Orally Administered Fisetin Reduces the Symptoms of Acute Allergic Asthma in a Preclinical Mouse Model

Background: Asthma is a very common, non-communicable, chronic respiratory disease, with high incidence rate worldwide. Currently, no permanent therapeutic strategies are available for the treatment of asthma. Drugs, such as corticosteroids, β2-agonists, and anticholinergics, only temporarily reduce symptoms have various adverse effects. In this study, we investigated use fisetin, readily natural product found in fruits, strawberries apples, to treat acute asthma preclinical mouse model. Methods: We induced BALB/c mice using intraperitoneal sensitization repeated intratracheal challenges ovalbumin (Ova), followed by oral administration 0.6 mg/kg (MPK) aqueous fisetin (primary stock DMSO) before each challenge. The were subsequently evaluated whole-body plethysmography, 24 hours after last challenge, measure airway hyper-responsiveness (AHR). sacrificed, their tissues removed evaluate range disease parameters. Results: treated AHR was significantly reduced, shown plethysmography. Acute inflammation associated also determined inhibition cellular infiltration, serum IgE, nitric oxide (NO), well reduction goblet cell hyperplasia. that potentially acts blocking TH2 response, including pro-inflammatory signaling molecules NFκB, STAT6, HIF1α, iNOS, TNFα IL13. Conclusion: Our study showed low dose (50 nM), administered orally an solution, may offer safe economical strategy